peptide-phi and Psoriasis

peptide-phi has been researched along with Psoriasis* in 1 studies

Other Studies

1 other study(ies) available for peptide-phi and Psoriasis

ArticleYear
Beta-adrenergic stimulation of cyclic AMP is defective in cultured dermal fibroblasts of psoriatic subjects.
    The British journal of dermatology, 1990, Volume: 122, Issue:4

    Epidermal cells from psoriatic lesions demonstrate a very low cAMP response to beta-adrenergic stimuli. We have shown that a similar abnormality occurs in dermal fibroblasts from affected areas of skin. The cells, after 5-12 passages in tissue culture, had a much reduced response to 10(-8) M and 10(-6) M isoproterenol when compared with fibroblasts from control subjects. The abnormality was not abolished by the addition of the phosphodiesterase inhibitor, 3-isobutyl-I-methylxanthine. Other putative agonists tested were vasoactive intestinal peptide and peptide histidine methionine. Neither of these had an effect on dermal fibroblasts from either normal controls or from lesions of psoriasis.

    Topics: 1-Methyl-3-isobutylxanthine; Adult; Cells, Cultured; Cyclic AMP; Female; Fibroblasts; Humans; Isoproterenol; Male; Peptide PHI; Psoriasis; Skin; Stimulation, Chemical; Vasoactive Intestinal Peptide

1990